Condition: Autoimmune Diseases · Rheumatoid Arthritis (RA) · Psoriatic Arthritis (PsA) · Sponsor: Seismic Therapeutic AU Pty Ltd
This is a multi-center, open-label Ph 1b basket study to assess safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, biomarker response, and preliminary efficacy of multiple doses of S-4321 in adults with autoimmune or immune-mediated disease including rheumatoid arthritis (RA), psoriatic arthritis (PsA), psoriasis (PsO), cutaneous lupus erythematosus (CLE) with or without systemic manifestations, or atopic dermatitis (AD).
This description comes directly from the study's public registry record.
Seismic Contact · 1800 244 475 · clinical@seismictx.com
Always discuss trial participation with your own doctor first.
| Novatrials | Charlestown, New South Wales, Australia | Recruiting |
| University of the Sunshine Coast Clinical Trials, Birtinya | Birtinya, Queensland, Australia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07455578